Headwinds from the pandemic have had varied effects on large cap medtech companies. Some have struggled – wrestling with supply chain concerns; hospital staffing shortages, and the soaring costs associated with the times. Other companies have relied on a diversified portfolio – one that contains diagnostics, to help offset any outside pressures.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,